HC Wainwright Reaffirms Buy Rating for Marinus Pharmaceuticals (NASDAQ:MRNS)

HC Wainwright reissued their buy rating on shares of Marinus Pharmaceuticals (NASDAQ:MRNS) in a report issued on Tuesday, Benzinga reports. The brokerage currently has a $27.00 price objective on the biopharmaceutical company’s stock.

A number of other equities research analysts have also commented on MRNS. Oppenheimer reaffirmed a market perform rating and set a $9.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. StockNews.com downgraded Marinus Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, March 6th. Finally, Royal Bank of Canada reiterated an outperform rating and set a $24.00 price objective on shares of Marinus Pharmaceuticals in a report on Wednesday, March 6th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of Moderate Buy and a consensus price target of $21.21.

Marinus Pharmaceuticals Trading Up 2.1 %

Shares of MRNS opened at $9.04 on Tuesday. The company has a quick ratio of 4.01, a current ratio of 4.07 and a debt-to-equity ratio of 5.68. Marinus Pharmaceuticals has a 12-month low of $5.57 and a 12-month high of $11.26. The firm has a market capitalization of $493.95 million, a PE ratio of -3.44 and a beta of 0.93. The stock’s fifty day simple moving average is $9.60 and its 200-day simple moving average is $8.45.

Marinus Pharmaceuticals (NASDAQ:MRNS) last released its earnings results on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The company had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same period in the previous year, the company posted ($0.76) EPS. As a group, research analysts predict that Marinus Pharmaceuticals will post -2.44 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. MetLife Investment Management LLC boosted its stake in shares of Marinus Pharmaceuticals by 63.8% during the 1st quarter. MetLife Investment Management LLC now owns 20,363 shares of the biopharmaceutical company’s stock worth $190,000 after acquiring an additional 7,928 shares during the period. Charles Schwab Investment Management Inc. lifted its holdings in Marinus Pharmaceuticals by 2.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 95,047 shares of the biopharmaceutical company’s stock worth $889,000 after purchasing an additional 2,281 shares during the last quarter. Renaissance Technologies LLC acquired a new position in Marinus Pharmaceuticals in the 1st quarter valued at $317,000. Goldman Sachs Group Inc. raised its holdings in Marinus Pharmaceuticals by 3.5% in the 1st quarter. Goldman Sachs Group Inc. now owns 156,949 shares of the biopharmaceutical company’s stock valued at $1,468,000 after acquiring an additional 5,380 shares in the last quarter. Finally, Quantbot Technologies LP acquired a new position in Marinus Pharmaceuticals in the 1st quarter valued at $40,000. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Company Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.